Related Experiment Video
Updated: Jun 2, 2025
Electromagnetic Navigation Transthoracic Nodule Localization for Minimally Invasive Thoracic Surgery
Published on: May 4, 2022
Validation of the 9th edition of the TNM staging system for limited-stage small cell lung cancer after Resection: A
Leilei Wu1, Jia-Yuan Tian2, Ming-Jun Li3
1Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310005, PR China; Department of Thoracic Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510000, PR China; Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, PR China.
Objectives:
The 9th edition of the tumor-node-metastasis (TNM) staging system for lung cancer was proposed at the 2023 World Conference on Lung Cancer in Singapore. This study aimed to externally validate and compare the latest staging of small-cell lung cancer (SCLC).
Methods:
Four hundred and eight patients with limited-stage SCLC were collected after lung resection from four centers. Survival curves by TNM stages were drawn using the Kaplan-Meier method and further compared by the Log-rank test. The Cox regression, receiver operating characteristics curves, area under the curve (AUC), Akaike information criterion (AIC), Bayesian information criterion (BIC), and Concordance index (C-index) were used in this study.
Results:
In comparing IA vs. IIB, IIA vs. IIB, IIA vs. IIIA, IIA vs. IIIB, and IIIA vs. IIIB, the 9th edition had a better distinguishing ability than the eighth staging system (all p < 0.05). Besides, the 9th edition TNM staging had better predictive power and accuracy for the overall survival (OS) of SCLC patients over the 8th edition (AUC of 3-year OS: 0.680 vs. o.668; AIC: 4425.25 vs. 4444.52; BIC: 4493.44 vs. 4512.71; C-index: 0.637 [0.04] vs. 0.629 [0.039], p < 0.001).
Conclusions:
Our external validation demonstrates that the ninth edition of pathological TNM staging for limited-stage SCLC is reasonable and valid based on a multicenter study. The ninth edition has better prognostic accuracy than the eighth edition.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019